1315 Capital Acquires Biocoat, Inc.
January 16, 2019
Philadelphia-based healthcare investment firm 1315 Capital has acquired Biocoat, Inc., a Horsham, Pennsylvania specialty manufacturer of hydrophilic biomaterial coatings for medical devices; the transaction closed on December 20, 2018. 1315 Capital's investment will provide expansion and growth capital to accelerate R&D, expand Biocoat's operating model, and support broader commercial efforts across neurovascular, cardiovascular, peripheral, and ophthalmic end markets.
- Buyers
- 1315 Capital
- Targets
- Biocoat, Inc.
- Industry
- Medical Devices
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
GTCR Invests in Biocoat
November 2, 2022
Medical Devices
GTCR has made a strategic, majority recapitalization investment in Biocoat Holdings, LLC, a Horsham, Pennsylvania-based provider of biocompatible hydrophilic coatings and dip-coating equipment for medical devices. Existing investor 1315 Capital and Biocoat management retain minority stakes; GTCR will partner with CEO Jim Moran and add industry veteran Chip Hance as Executive Chairman to support growth, capability expansion and follow-on acquisitions.
-
1315 Capital Acquires SciSafe from BioLife Solutions
November 14, 2024
Healthcare Services
1315 Capital, a Philadelphia-based growth equity firm, has acquired SciSafe from BioLife Solutions in an all-cash transaction that establishes SciSafe as an independent, standalone biostorage company. The deal accompanies a growth capital investment to fund expansion of SciSafe's biostorage, cold-chain and compliance capabilities and to support global footprint growth.
-
1315 Capital Invests in Primrose Bio
June 17, 2024
Biotechnology
1315 Capital, a Philadelphia-based healthcare-focused growth equity firm, made a significant equity investment in Primrose Bio to support development and commercial expansion of Primrose’s nucleic acid and protein manufacturing technologies. The funding will accelerate commercialization of the company’s Prima RNApols, Pfenex expression system, and PeliCRM carrier protein for therapeutics and vaccines.
-
1315 Capital Backs USpharma Ltd. with Growth Equity Investment
June 30, 2025
Pharmaceuticals
USpharma Ltd., a Miami Lakes-based pharmaceutical development and manufacturing company, received a growth equity investment from Philadelphia-based 1315 Capital. The capital will be used to accelerate development and commercialization of USpharma’s pipeline, expand commercial reach, and scale operations at its 150,000 sq. ft. US-based GMP facility.
-
1315 Capital Leads Growth Investment in Experic
October 29, 2024
Pharmaceuticals
Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.
-
Biocomposites Takes Minority Stake in Renovos Biologics
July 5, 2023
Biotechnology
Biocomposites has taken a minority equity stake in Renovos Biologics to support development and pre-market approval of the RENOVITE nanoclay therapeutic delivery platform. The investment will give Renovos access to Biocomposites' development expertise and global distribution network; Biocomposites CEO Michael Harris will join Renovos' board.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.